American International Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

American International Group’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,514	Closed	-$85K	–	4794
2016 Q1	$85K	Hold	4,514	–	–	﹤0.01%	3559
2015 Q4	$120K	Sell	4,514 -8	-0.2%	-$278	﹤0.01%	3345
2015 Q3	$207K	Buy	4,522 +5	+0.1%	+$189	﹤0.01%	2791
2015 Q2	$145K	Sell	4,517 -322	-7%	-$9.36K	﹤0.01%	3328
2015 Q1	$154K	Sell	4,839 -12	-0.2%	-$406	﹤0.01%	3189
2014 Q4	$183K	Sell	4,851 -175	-3%	-$4.81K	﹤0.01%	3027
2014 Q3	$133K	Sell	5,026 -4	-0.1%	-$106	﹤0.01%	3315
2014 Q2	$149K	Buy	5,030 +864	+21%	+$27.9K	﹤0.01%	3253
2014 Q1	$154K	Buy	4,166 +98	+2%	+$3.72K	﹤0.01%	3066
2013 Q4	$168K	Sell	4,068 -40	-1%	-$1.56K	﹤0.01%	2910
2013 Q3	$218K	Buy	4,108 +329	+9%	+$19.2K	﹤0.01%	2654
2013 Q2	$202K	Buy	+3,779	New	+$189K	﹤0.01%	2556

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

American International Group's NAVB Position: Q2 2016 in Review

American International Group sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 4,514 shares — an estimated $85K sold.

American International Group first reported a position in NAVB in Q2 2013 and held it in 12 quarters. The position peaked at $218K in Q3 2013. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

American International Group reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
American International Group sold 4,514 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $85K.
American International Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 12 quarters.
American International Group's Navidea Biopharmaceuticals Inc. position peaked at $218K in Q3 2013.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on American International Group's 13F filing for Q2 2016, filed 11 Aug 2016.